I n recent years, transcatheter aortic valve implantation has become an emerging alternative for high-risk patients with severe aortic stenosis. Midterm outcomes compare favorably with conventional open heart surgery in selected patients. A promising new indication in this technology could be the interventional treatment of degenerated bioprostheses.
Here, we report about a "valve in valve" implantation of the CoreValve prosthesis (Medtronic, Inc; Minneapolis, Minn) in a degenerative, Epic stented biological prosthesis (St Jude Medical; St Paul, Minn) in a patient with acute aortic regurgitation. A male patient aged 79 years with previous surgical valve replacement 5 years ago was admitted to the hospital with acute dyspnea (New York Heart Association class III to IV). At physical examination, a diastolic murmur (grade 4) and a blood pressure of 130/50 mm Hg were noted. Transthoracic and transesophageal echocardiography showed degeneration of the 23-mm Epic stented bioprosthesis with severe central aortic regurgitation due to cusp prolapse (online-only Data Supplemental Videos I and II). Furthermore, echocardiographic measurements are summarized in the Table. Coronary angiogram revealed coronary artery disease without significant stenoses. Aortic root angiogram (supplemental Video III) confirmed severe aortic regurgitation (grade III to IV) in concordance with the findings on echocardiography. Because of previous cardiac surgery and comorbidities, perioperative risk was regarded as significantly increased, with a calculated logistic EuroSCORE of 23% and Society Thoracic Surgeons risk score of 9.5%. Thus, a percutaneous approach was considered as a bail out procedure.
Computed tomographic scan of the great arteries was performed ( Figure 1 ) to evaluate the patient for percutaneous valve replacement. Having informed consent and approval by the institutional review board, the procedure was performed under local anesthesia. A third-generation 26-mm CoreValve prosthesis was successfully implanted through the right femoral artery (supplemental Videos IV through VI). Final aortic root angiogram showed no aortic regurgitation. The end-diastolic pressure in the left ventricle immediately decreased from 50 to 20 mm Hg ( Figure 2 ). No postprocedural complications were noted, and the patient was discharged 6 days after the procedure with significantly improved symptoms (New York Heart Association class I). At 6 months follow-up, transesophageal echocardiography confirmed adequate position of the prosthesis with the absence of residual regurgitation (supplemental Videos VII and VIII). The patient remained free of symptoms with functional New York Heart Association class I. ECG-gated, 256-slice cardiac computed tomography demonstrated stable valve-in-valve prostheses with completely expanded circular frame geometry (Figure 1) .
Presumably because of extended use of bioprosthetic valve replacement and ageing of the population, the number of degenerative bioprostheses will increase in the future. More comorbidities with increasing age may reduce eligibility for a second cardiac surgery in many patients. As already shown in several studies, transcatheter valve implantation has been proven to be feasible for severe aortic stenosis using either self-or balloon-expandable prostheses. So far, there are only a few reports 1-4 on valve-in-valve procedures in patients with degenerative aortic bioprostheses. Here, we described the interventional treatment of a degenerative bioprosthesis in a case with acute severe regurgitation, using the CoreValve prosthesis implanted in a failed Epic biological prosthesis. This valve-in-valve approach and the excellent hemodynamic outcome led to a fast and uneventful recovery in our patient. Our case demonstrates that percutaneous therapy of degenerative bioprostheses is a feasible and safe procedure, even in the setting of acute aortic regurgitation. However, percutaneous valve-in-valve implantation is considered to be technically even more demanding than implantation into a native valve because the self-expanding valve is delivered into the annulus of a bioprosthesis with a rather unflexible fixed diameter, further augmenting the movement of the valve toward the left ventricular cavity. This trend toward too-low implantation of the prosthesis can usually be compensated only by starting to open the valve just below the annulus and carefully counterbalancing the forces that tend to direct the valve into the ventricular cavity. Because the annular design of the various bioprostheses can be quite different, some of these valves might qualify more for such procedures than others.
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